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Background. Understanding the mechanisms of simian immunodeficiency virus (SIV) 
emergence in a new host is a major public health priority, as both HIV-1 and HIV-2 emerged 
through cross-species transmissions from their respective chimpanzee and sooty mangabey (SM) 
hosts. We therefore studied the factors associated with the fate of cross-species transmitted SIV 
infection to a new host by comparing and contrasting controlled and progressive cross-species 
transmitted SIV infections in an African non-human primate (NHP), the Guinea baboon (Papio 
papio). Baboons, a non-natural host of SIV, were previously reported to carry SIVagm from 
African green monkeys (AGMs) in the wild and to progress to AIDS when experimentally 
infected with SIVsmm from SMs. 
Methods. Ten baboons were intravenously infected with either SIVsab, the virus 
naturally infecting the sympatric AGMs (Chlorocebus sabaeus) or SIVsmm that naturally infects 
SMs (Cercocebus atys). The impact of intrinsic immunity on SIV infection was assessed by (i) 
monitoring temporal changes in the host restriction factor (HRF) (APOBEC3G, TRIM5α, 
SAMHD-1, tetherin and MX2) expression in lymph nodes (LNs) by immunohistochemistry 
(IHC) and (ii) virus evolution through single genome amplification and sequencing.  
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Results. Upon exposure to SIV, the viral loads (VLs) peaked at 10-14 days post infection 
(dpi). Peak VLs were 2-3 logs lower in SIVsab infected baboons, who controlled the virus to 
undetectable levels at 28-42 dpi and then through follow-up. Conversely, SIVsmm infection was 
persistent throughout the follow-up and two out of four SIVsmm infected baboons showed signs 
of disease progression. IHC quantification revealed an increase in the expression of individual 
HRFs in the LNs from SIVsab infected controller baboons. Conversely, HRF expression was 
virtually unchanged in SIVsmm infected baboons and in AGM natural hosts. SIV quasispecies 
characterization identified a mutation rate similar to that observed in the natural host in baboons 
infected with SIVsmm and baboons infected with SIVsab.  
Conclusions. Our results demonstrate that combined rather than individual action of 
HRFs is the major determinant of the outcome of SIV infection upon cross-species transmission. 
Therefore, approaches aimed at developing new animal models for HIV research should 
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1.0  INTRODUCTION 
The AIDS pandemic caused by human immunodeficiency virus (HIV) is a large health, 
economic, and societal burden. With 36 million lives already claimed and 36 million patients 
currently infected by HIV, it is necessary to devote resources in an effort to curb the destruction 
caused by HIV (57). Major progress has been achieved in understanding how the virus is spread, 
allowing for many public health education programs to prevent new infections.  Although 
expensive and not accessible to all who need them, more antiretroviral drugs were developed for 
HIV and are currently available than for all other viral infections combined. Altogether, 
antiretroviral therapy (ART) dramatically improved the prognosis of HIV infection, current life 
expectancy of a newly infected subject being 59 years (14). Still, ART cannot cure infection and 
no effective vaccine to prevent HIV infection is available thus far.  
HIV emerged following cross-species transmissions of the lentiviruses naturally infecting 
nonhuman primate (NHP) species in Africa, which are generically called simian 
immunodeficiency viruses (SIVs). A successful infection via cross-species transmission is 
dictated by many host and viral factors. Understanding the role these factors have on the success 
or failure of a cross-species transmission event is an essential part of understanding how HIV 
establishes infection to cause disease, how to prevent more SIVs from jumping the species 
barrier to humans, and emergence of new epidemic/pandemic strains. 
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1.1 CROSS-SPECIES TRANSMISSION 
Viruses are usually limited to a specific host range as determined by a combination of 
many host defense and virus specific factors. Generally, most cross-species transmission events 
are dead-ends, but occasionally a virus can successfully cross the species barrier and successfully 
spread within a new population. The mechanisms by which cross-species transmission occurs are 
specific to each virus-host combination and are not well understood. 
Many viruses have crossed the human species barrier to humans and some have spread in 
the human population. Ebola virus’ natural host is believed to be Fruit bats, but highly lethal 
outbreaks spill over and spread into the human population through contact with bat urine or 
feces. Ebola is also spread from human to human by contact with an infected person’s bodily 
fluids (81). Like Ebola, the Rabies virus natural host is believed to be bats and is spread to wild 
animal through bat urine or feces. Rabies virus transmission to humans is very rare and usually 
occurs via saliva from the bite of an infected wild animal Even more rare is human to human 
transmission, unlike Ebola virus (79). Influenza virus infects humans, birds, and pigs, among 
other mammals. Influenza can cross the species barrier by using genetic reassortment and genetic 
drift to evolve past species barriers (67).  
As previously mentioned, HIV-1 and HIV-2 are products of successful cross-species 
transmission from SIVchz and SIVsm respectively. HIV-1 is global and is considered more 
pathogenic while the less pathogenic HIV-2 is limited to West Africa. In a study that tested 5 
subtypes of HIV-2, only 2 were pathogenic while 3 were dead ends (19). However, not all cross-
species transmission events are successful, as one human tested positive for antibodies specific to 
SIVmnd, but did not develop disease from the virus (74). Furthermore, there are reports of 
African hunters exposed to SIVs through hunting and butchery who show no signs of clinical 
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disease (29). The mechanisms that determine the success or failure of an SIV cross-species 
transmission event are largely undetermined. 
1.2 HOST RESTRICTION FACTORS 
Host restriction factors (HRFs) are proteins that exhibit antiviral properties. HRFs can 
completely or partially inhibit viral replication and may play a role in the success or failure of 
cross-species transmission. In general, HRFs are products of IFN-stimulated genes and thus can 
block virus transmission as part of the broadly-acting interferon (IFN) responses. Note, however, 
that the transmitted/founder strains were reported to be  more resistant to IFNs, which explain 
why cross-species transmissions of SIVs between NHP species and between NHPs and humans 
can occur (17). In response to this virus adaptation, multiple HRFs act uniquely in different 
hosts, with different viruses, and at different stages of the viral life cycle.  
Currently, six SIV/HIV host restriction factors have been identified: APOBEC3g (47), 
MX2 (24, 30), SAMHD1(37, 38), Tetherin (36, 55), TRIM5α (76), and, most recently, nuclear 
export inhibitor HERC5 (82). While there are most likely many more HRFs yet to be discovered, 
this study focuses on five (APOBEC3g, SAMHD1, Tetherin, TRIM5α, MX2) HRFs potentially 
working together, in concert, to have an overall effect on viral replication.  
1.2.1 APOBEC3g 
In 2003, APOBEC3g, formerly known as CEM 15, was the first HIV specific host 
restriction factor discovered (84). APOBEC3g is an acronym for apolipoprotein B mRNA-
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editing, enzyme-catalytic, polypeptide-like 3G (73), and is the most potent host restriction factor 
of the several siblings in the APOBEC family of proteins (84). APOBEC3g has two forms: an 
inactive high-molecular-mass (HMM) and an enzymatically active Low-molecular-mass (LMM) 
form (11). While APOBEC3g is primarily expressed in CD4
+
 T cells, dendritic cells and 
macrophages (the primary targets of the HIV virus) it has also been found in other cell types 
upon IFN stimulation (75). An important caveat is that APOBEC3g must be packaged into HIV 
virions as they are exiting an infected cell and acts against HIV in newly infected cells (31).  
APOBEC3g acts as a cytosine deaminase thereby removing the amine functional group 
from cytosine converting it to uracil on the negative strand of DNA during reverse transcription 
(84). This base pair modification affects the complementary positive strand DNA (G to A 
mutations) and subsequent mRNA products to induce potentially fatal mutations or drive HIV 
evolution. In vitro studies have also suggested that APOBEC3g works to inhibit reverse 
transcription altogether by: competitively binding tRNA, inhibiting strand transfer, and inhibiting 
elongation of reverse transcription products (50). However, these functions have yet to be 
verified in vivo (50).   
APOBEC3g is antagonized by the auxiliary protein Vif in HIV viruses. Vif marks 
APOBEC3g for ubiquitin degeneration by host proteasomes, thus preventing it from being 
packaged into the progeny HIV virions (31).  Additionally, some evidence suggests that Vif 
directly inhibits encapsidation and impairs translation of APOBEC3g (50). 
1.2.2 TRIM5α 
In 2004, the second HIV host restriction factor, TRIM5α, was discovered in Owl 
monkeys, which are resistant to HIV-1 infection (70). TRIM5α is a member of the tripartite 
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motif (TRIM) family of proteins. Structurally, it contains: RING domains, B-boxes, coiled coils, 
and a unique carboxy-terminal B30.2 (SPRY) domain not found in the other TRIM5 proteins 
(76). The RING and SPRY domains are required for antiviral activity, while the B-Box domains 
assist with but are not required for antiviral function (76). Typically, TRIM5α is located in the 
cytoplasm of cells, but it also localizes into cytoplasmic bodies (76). Both forms exhibit antiviral 
capabilities (76).  
TRIM5α can restrict a wide range of retroviruses and seems to better restrict retroviral 
variations outside of host species. For example, rhesus macaque TRIM5α restricts HIV-1 better 
than human TRIM5α (76, 78). Usually the host TRIM5α does little to restrict the virus when it is 
in the natural host. Human TRIM5α does little to restrict HIV-1 (76, 78). Thus, TRIM5α can be 
an excellent mediator of cross-species transmission.  
TRIM5α’s exact mechanism of restriction is still unclear, but there have been some 
important clues. First, TRIM5α binds to capsid proteins and appears to accelerate capsid 
uncoating (77).  Premature uncoating itself may disrupt the formation of the reverse transcription 
complex, thereby inhibiting viral replication. It is also believed that the SPRY domain is 
important in restriction. One group made chimera TRIM5α proteins by adding an rhTRIM5α 
SPRY domain to a human TRIM5α, and found that particular chimera is sufficient for HIV-1 
inhibition (78). Another mechanistic clue is cyclophilin A. TRIM5α is associated with the 
cyclophilin A protein. Furthermore to support the relationship between TRIM5α and cyclophilin 
A, there are reports of a TRIMcyp fusion protein with restrictive properties (56). cyclophilin A’s 
association with TRIM5α can help or hinder viral restriction depending on the host and virus 
combination as some viruses have mutations that prevent cypA binding (77).  
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1.2.3 Tetherin 
Interestingly, tetherin’s existence was predicted before it was discovered. An IFN-
induced tethering mechanism acted against HIV virion release that was absent in the presence of 
Vpu supplied the rationale for a microarray search for the protein responsible (45). Tetherin 
(CD317 or BST-2) was identified in 2008 by Niel et al. as a broadly acting protein against many 
viruses including Lassa virus, Ebola virus, HIV, and SIV (55). Tetherin is an IFN induced 
protein (55). Tetherin is present on many cell types, including dendritic cells (13), macrophages 
(12), and T cells (28). It can be located in the cellular membrane or in the trans-Golgi region of 
the cell in endosomes (54). 
Tetherin prevents cell-to-cell spread of HIV infection by binding the virus particles to 
plasma membrane therefore inhibiting the necessary budding of viral progeny (36, 55).  
Structurally, tetherin has one transmembrane region that remains in the viral envelope and an 
anchor region that remains in the host cell membrane. These regions are separated by a long α-
helix that has a dimeric, coiled structure (45).  
Tetherin is antagonized by three retroviral proteins: Vpu, Nef, and Env. Vpu antagonizes 
tetherin by marking it for degradation (46), or by binding directly to tetherin preventing it from 
reaching the cell surface (45).  In viruses without Vpu, there is evidence suggesting that either 
Nef or Env proteins can deter tetherin function; however detailed mechanisms have yet to be 
deciphered (45).  
7 
1.2.4 SAMHD1 
SAMHD1 stands for SAM domain and HD domain-containing protein 1 and is expressed 
in dendritic cells, macrophages, and monocytes (37). SAMHD1 usually resides in the nucleus of 
cells except for those SAMHD1 proteins without a nuclear location sequence (8). Both nuclear 
and cytoplasmic forms have antiviral capabilities (25). Crystallography reveals that inactive 
SAMHD1 has a dimer structure with a major and a minor groove (23). dGTP binds to convert 
SAMHD1 into its enzymatically active form SAMHD1c (23). Together these clues suggest that 
SAMHD1 interferes with HIV replication. 
IFN-induced SAMHD1 has an enzymatic function that converts nucleotides to 
nucleosides, thereby depleting the pool of available nucleotides for replication (38). 
Interestingly, SAMHD1 will only hydrolyze GTP when each nucleotide is tested individually, 
but will hydrolyze all four nucleotides when all are present (23). SAMHD1’s depletion of 
available nucleotides for replication limits reverse transcription and, therefore, HIV infection.  
Depending on cellular location, Vpx can antagonize SAMHD1, or vice versa. In the 
nucleus, Vpx antagonizes SAMHD1 by recruiting ubiquitin ligases that mark it for degradation 
in proteasomes (25). In the cytoplasm, SAMHD1 binds Vpx, preventing it from reaching the 
nucleus. Even in the presence of Vpx, cytoplasmic SAMHD1 retains antiviral ability (25). 
1.2.5 MX2 
Myxovirus resistance 2 (MX2) was identified as an HIV host restriction factor in the fall 
of 2013 by Malim et al. despite having been well studied for many years (24).  MX1, MX2’s 
cousin, has marked antiviral activity against influenza virus, but not HIV/SIV. Conversely, MX2 
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does not exhibit any antiviral activity against influenza virus, but has antiviral properties against 
HIV (24). This protein shows some inhibitory effects on various types of SIV, but most notably 
with HIV-1 in various cell lines (24, 30).  
While the mechanism of action has yet to be determined, MX2 associates with 
cyclophilin A and loses potency when HIV-1 mutates its capsid protein at residue 88 (30). This 
suggests that MX2 acts on HIV’s capsid in a cyclophilin A-dependent manner (30). MX2 is 
thought to interfere with HIV DNA’s entry into the nucleus or its integration into host DNA, as 
nuclear aggregation of virus and viral cDNA is suppressed in the presence of MX2 (24). MX2 is 
located either in the nucleus itself or in the cytoplasm around nuclear pores, thus supporting the 
hypothesis of nuclear entry/integration interference (24). IFN-α stimulation is required for 
MX2’s antiviral properties (24, 30). Considering MX2’s recent identification, not much is known 
about other functions MX2 may have or what mechanisms of evasion HIV may employ against 
it. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Most studies investigating the role of HRFs in preventing/controlling HIV/SIV infection 
in a new host upon cross-species transmissions were performed in vitro, on cell lines and 
generally focused on single host restriction factors. However, their effects might be less clear-cut 
in vivo, but the overall impact might be critical on HIV/SIV pathogenesis and transmission. The 
case in point is the impact of TRIM5α genotypes on the outcome of chronic SIVsmm infection in 
RMs. While in vitro studies did not find such impact, in vivo, different TRIM5α pedigrees of 
RMs might result in variations of the set point viral loads of 10-1000 fold. We, therefore, 
developed an animal model system to monitor the impact of HRFs alone or in combination with 
the outcome of cross-species transmitted SIV infection. 
Our overall hypothesis is that the combined action of multiple host restriction factors 
will have an overall impact on the control of SIVsab infection in baboons. The use of this 
cross-species transmission animal model will provide an excellent environment to assess the role 
of HRFs as major contributors to the overall success or failure of cross-species transmitted SIV 
infection.  
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2.1 AIM 1: TO COMPARE AND CONTRAST THE NATURAL HISTORY AND THE 
OUTCOME OF SIVSAB OR SIVSMM INFECTION IN GUINEA BABOONS (PAPIO 
PAPIO). 
Rationale: Our overall goal is to establish the appropriate animal models to assess 
impact of host restriction factors on the outcome of the cross-species transmitted viral infection. 
While both SIVsab and SIVsmm are cross-species transmitted, our hypothesis is that SIVsab and 
SIVsmm infections will have opposite outcomes in the same baboon species. Therefore, we can 
use these systems to assess the role of HRFs in these different infection outcomes. As controls, 
we employed SIVsab in its natural host, AGMs, in which the impact of restriction factors should 
be minimal.  Hypothesis:  Our hypothesis is that baboons will control the SIVsab infection, but 
will progress to AIDS when infected with SIVsmm. Due to these major differences in the natural 
history of infection, these two models of SIV infection represent perfect settings for studying 
host restriction. Approach: Compare and contrast the natural history of SIV infection in the two 
models by 1) quantifying viral loads in baboons infected with SIVsab or SIVsmm, 2) examining 
the impact of infection on relevant immune cell populations, and 3) quantifying the levels of 
systemic immune activation in the two models of progression. Significance: The study of two 
models with completely different SIV infection outcomes offers us an ideal experimental 
environment to assess the role played by the host restriction factors in SIV cross-species 
transmission. 
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2.2 AIM 2: TO DIRECTLY ASSESS THE CHANGES IN HOST RESTRICTION 
FACTORS THAT MAY CORRELATE WITH VIRUS CONTROL UPON CROSS-
SPECIES TRANSMISSION. 
Rationale:  Use of two infection models with opposite natural histories of SIV infection 
based on the same NHP species will permit us to assess the most discrete changes in the HRFs 
that may play a role in viral control. Our goal is to examine changes in expression of host 
restriction factors at key time points of SIV infection and control.  Hypothesis: While each 
restriction factor acts on different stages of replication and each plays a role in the control of 
cross-species transmission, it is their aggregated action that will drive the overall outcome of 
infection. HRF expression will increase in controllers, but will remain constant in progressor 
baboons and in the natural host. Approach:  Our approach uses histological techniques to assess 
dynamics of HRF expression in lymph nodes by 1) an immunohistochemistry (IHC) assessment 
of HRF protein expression, 2) Quantification of IHC signals, and 3) Immunofluorescence (IF) 
double stain to attribute expression of HRFs to specific immune cell population(s). Significance: 
This study will examine the expression of five HRFs working in concert to influence the impact 
of infection, while many studies only focus on one or two of the HRFs. 
2.3 AIM 3: TO ASSESS THE HRF IMPACT ON THE VIRUS IN CONTROLLED 
AND PROGRESSIVE INFECTIONS OF BABOONS. 
Rationale: This study will directly assess the effects of APOBEC3g on the virus by 
monitoring the evolution of the virus quasispecies in controllers and progressors. Hypothesis: A 
12 
higher APOBEC3g induced G-A hypermutation rate will be observed in controllers and will be 
directly correlated with the over expression of HRFs. Approach:  Single genome amplification 
(SGA) and analysis of SIV quasispecies diversity will be performed to assess hypermutations 
and sequence changes that might be illustrative of host evolutionary pressures. Significance: 
This approach will directly assess the impact of HRF on the virus itself, an innovation yet to be 
seen in this field. 
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3.0  STUDY DESIGN 
3.1 THE BABOON IS AN IDEAL ANIMAL MODEL TO STUDY CROSS-SPECIES 
TRANSMISSION OF SIV/HIV 
Due to practical and ethical concerns, the study of SIV cross-species transmission cannot 
be directly investigated using human subjects. Ethically, one cannot infect humans with 
potentially dangerous viruses. Practically, a natural cross-species transmission is not usually 
caught early enough during infection to assess the complex requirements and virus-host 
interactions necessary for a successful cross-species transmission. Furthermore, if a cross-species 
event was to occur, the detection tools and methodology may not be readily in place to detect 
such an event. For example, SIVs have a tremendous genetic diversity while the serology and 
PCR-based detection kits only cover the diversity of HIV strains, which represent only a minor 
fraction of the total genetic diversity.  Instead, animal models are an acceptable alternative to 
studying cross-species transmission of SIV/HIV.  
With a number of potential animal models available for AIDS research, one should 
choose the best animal model to study the mechanisms and requirements of a successful cross-
species transmission. Ideally, such an animal model must use an African species that is not a 
natural host of SIV. An African species is more likely to have a similar evolutionary history and 
ecological features with the natural host. Importantly, a non-natural host of SIV will not have 
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evolutionary adaptations to SIV. The animal model must compare and contrast the natural 
history of SIV infection in the new host and in its natural host, and biologically monitor multiple 
cross-species transmissions with opposite outcomes of infection. Together these considerations 
should allow us to better understand the requirements for a successful cross-species transmission. 
Baboons could serve as an ideal animal model for HIV/SIV investigations, though 
typically rhesus macaques (RMs) and pigtailed macaques (PTMs) are used to study HIV/SIV. 
Baboons are not endangered, are larger animals (which is good for large volume blood draws), 
and breed well in captivity (41). Unlike other NHPs, baboons do not carry the Herpes B virus 
that is potentially lethal to human researchers (41). Baboons are closely related to both humans 
and to macaques. In fact, baboons and rhesus monkeys can mate to make a sterile offspring 
called a rheboon (41). Like humans, baboons have four subclasses of IgG antibody, whereas 
Rhesus monkeys only have three suggesting this model is closer to humans immunologically 
(41). Baboons have been used in numerous studies relating to a wide variety of human diseases 
(41), and have been used to test HIV vaccine components (9, 10, 39, 42). Baboon blood marrow 
was even used safely in a failed cure transplant attempt for an AIDS patient (49). 
Furthermore, baboons are an African NHP species that are not natural hosts of SIV with 
no baboon-specific SIV being described to date (41). However, multiple species of baboons have 
been shown to carry SIVs in the wild (in general cross-species transmitted from the sympatric 
AGM species) (26, 35, 80). The first molecular evidence for an SIV cross-species transmission 
has been reported in a yellow baboon infected with SIV from AGMs (26). While there are a few 
cases that suggest SIVs can infect baboons in the wild, it is not known whether baboons progress 
to an AIDS-like disease status naturally.  
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Upon experimental exposure, baboons have shown ability to control cross-species 
transmitted SIVs/HIVs. Thus, baboons infected with SIVmne (6), HIV-1 (52), and SIVmac (15) 
showed signs of swollen lymph nodes indicative on infection; yet, they demonstrated 
inconsistent seroconversion, with little–to-no virus  isolated from the blood and  no  signs of 
clinical disease. Only when infected with the simian-human immunodeficiency virus (SHIV) 
chimera could the virus be more readily detected in the blood, yet the animals still did not 
present any signs of clinical disease (1, 34). Upon initial experimental infection with HIV-2, 
Hamadryas baboons showed similar infection patterns as mentioned previously, but upon serial 
passages, the virus became more pathogenic eventually resulting in an AIDS-like disease (43). 
Disease progression was more similar to that in humans than other animal models, with high 
viral loads and CD4
+
 depletion in the acute phase, a roughly four to seven year healthy phase, 
and finally a development of an AIDS-like disease (43). Acute infection was initially controlled 
by CD8
+
 T cells like human infections (7), and neutralizing antibody response developed at 
roughly six months and peaked one year post infection (43). It was, therefore, concluded that due 
to the similar natural history of infection with HIV-1 infection, baboons can be used as an animal 
model for HIV disease. 
For our study, we opted for the use of Guinea baboons (Papio papio), which are the 
baboon species specific to West Africa. The rationale for choosing Guinea baboons is that they 
are sympatric to the Western species of AGMs, the sabaeus monkey. This is the species 
extensively used in our lab.  We reasoned that since cross species transmission occurred in the 
wild at different locations (i.e., Kenya and South Africa) between the sympatric AGM and 
baboon species, the proposed match should be the option of choice for such cross species 
transmission studies. 
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3.2 CHOOSING A VIRUS FOR THE STUDY OF CROSS-SPECIES TRANSMISSION 
For our studies on cross-species transmission, we employed two SIV strains: 
SIVSab92018, a virus isolate naturally infecting the West African sabaeus African green 
monkeys (Chlorocebus sabaeus), and SIVsmm, a virus isolated from the sooty mangabeys 
(Cercocebus torquatus atys). While naturally infecting AGMs, SIVagm has been shown to infect 
baboons in the wild (26). In particular, SIVsab92018 (from here on referenced as SIVsab) strain 
is ideal for this cross-species transmission study as it has never been passaged in vitro, was 
collected from an acutely infected sabaeus monkey, and has a diverse inocula containing a large 
proportion of transmitted founder viruses, as shown in previous studies from our lab (3, 5, 21, 
22, 62). As Guinea baboons are sympatric and eat AGMs, a plausible route of cross-species 
transmission can be established in the wild between these two species. To date, it is not known 
whether baboons progress to AIDS when infected with this virus. 
SIVsab has been used in multiple animal model studies. In its natural AGM host, SIVsab 
causes persistent but nonpathogenic infection (63). Similarly, in the African NHP species, the 
patas monkeys, SIVsab induces high levels of persistent viral replication with no disease 
progression (3). SIVsab is pathogenic in pigtailed macaques (PTMs) (61), while RMs control the 
infection (62). 
SIVsmm naturally infects sooty mangabeys (SMs) and is the ancestral virus of HIV-2 
(72). After serial passage, HIV-2 was shown to cause AIDS-like disease in baboons 
experimentally (41, 44), which allowed us to hypothesize that an unadapted SIVsmm transmitted 
founder strain may cause AIDS-like disease in baboons. This study is the first experimental 
infection with SIVsmm in baboons. 
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Experimentally, SIVsmm infection can result in a wide variety of disease outcomes in 
NHP animal models. SIVsmm is generally nonpathogenic in its natural hosts, the sooty 
mangabeys, despite high viral loads (33), with only one case of AIDS being described in an old 
SM that outlived the lifespan of the species (40). Upon cross species transmission, a case of 
AIDS was also reported in a black mangabey infected with SIVsmm (4). Upon cross-species 
transmission to Asian NHP species, SIVsmm is pathogenic in rhesus macaques (83) and 
pigtailed macaques (18). 
Both viruses used in this study retain the traditional lentiviral structure of encoding 
regions 5’-gag-pol-env-3’ that are flanked by two long terminal repeats (53).  The gag encoding 
region produces the capsid proteins P24, P17, and NC (53). The Pol encoding region produces 
the nonstructural proteins of reverse transcriptase, and protease (to cleave viral polyproteins into 
individual active proteins) (53). The Env encoding region encodes the envelope proteins of 
Gp120 and Gp41 used for attachment and entry into the host cell (53).  
SIVs may contain a number of accessory proteins that have been associated with 
virulence in addition to replication functions. In general, all lentiviruses and both viruses used in 
this study have vif, vpr, nef, tat, and rev (71). The presence of vpx and vpu is variable depending 
on the virus. For example, HIV-1 encodes Vpu, but not Vpx (71). SIVagm does not have 
accessory proteins Vpx or Vpu, while SIVsmm encodes only Vpx (71).  Of note, these accessory 
proteins are antagonists to some host restriction factors as mentioned previously. For example, 
Vpu antagonizes tetherin (55); Vif antagonizes APOBEC3g (48); and Vpx antagonizes SAMHD1 
(25). Lack of Vpx in SIVsab may render this strain insensitive to this restriction factor. 
18 
4.0  MATERIALS AND METHODS 
4.1 NHPS AND INFECTIONS 
This study involved 10 Guinea baboons and 28 African green monkeys (AGMs). Six 
baboons were challenged intravenously (IV) with plasma equivalent of 300 Tissue Culture 
Infectious Doses 50% (TCID50) of SIVagmSab92018 (60) and four were challenged IV with 
plasma equivalent of 300 TCID50 of SIVsmmD215 (20). All AGMs were infected IV with 
plasma equivalent of 300 TCID50 of SIVagmSab92018. The animals and infection were 
monitored for up to 8 months post infection. 
The animals were housed at the RIDC Park facility of the University of Pittsburgh in 
accordance with the recommendations of the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) International Standards and with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (2). 
The Institutional Animal Use and Care Committee of the University of Pittsburgh approved these 
studies (Protocol # 09039). Efforts were made to minimize animal suffering in agreement with 
the recommendations of the Weatherall report, "The use of non-human primates in research". 
The RIDC Park facility is air-conditioned, with an ambient temperature of 21-25°C, a relative 
humidity of 40%-60% and a 12 h light/dark cycle. Animals were individually housed in 
suspended stainless steel wire-bottomed cages and provided with a commercial primate diet. 
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Fresh fruit was provided once daily and water was freely available at all times. A variety of 
environmental enrichment strategies were employed including housing of animals in pairs, 
providing toys to manipulate and playing entertainment videos in the animal rooms. In addition, 
the animals were observed twice daily and any signs of disease or discomfort were reported to 
the veterinary staff for evaluation. For sample collection, animals were anesthetized with 10 
mg/kg ketamine HCl (Park-Davis, Morris Plains, NJ, USA) or 0.7mg/kg tiletamine HCl and 
zolazepan (Telazol, Fort Dodge Animal Health, Fort Dodge, IA) injected intramuscularly. The 
animals were sacrificed by intravenous administration of barbiturates prior to the onset of any 
clinical signs of disease. 
4.2 BLOOD AND TISSUE COLLECTION AND PROCESSING  
Blood, lymph nodes (LN), and intestinal biopsies (IB) were collected throughout the 
follow-up as follows: preinfection, at multiple time points of the acute infection, including the 
viral peak, at the viral set point, during the chronic infection, and at the necropsy. Blood was 
collected at -14, 0, 7, 10, 15, 22, 29, 43, 73, 101, 134, 166 days post infection (dpi) and at the 
necropsy. LNs were collected at 0, 10, 29, 101 dpi and at the necropsy. Intestinal fragments of 
the intestine (jejunum) were obtained by endoscopic guided biopsy at 0, 22, 29, 43, and 101 dpi 
with additional samples collected at the necropsy. 
Within one hour after blood collection, plasma was harvested and peripheral blood 
mononuclear cells (PBMCs) separated from the blood using Ficoll density gradient 
centrifugation, as described (66). Lymphocytes from the intestine and LNs were isolated and 
stained for flow cytometry, as previously described (60, 65, 66). Lymphocytes were isolated 
20 
from the axillary or inguinal LNs by gently mincing and pressing tissues through nylon mesh 
screens (60, 65, 66). Intestinal resections were processed as follows: minced mechanically, 
washed with EDTA, and subjected to collagenase digestion followed by Percoll density gradient 
centrifugation, as described (60, 65, 66). 
4.3 FLOW CYTOMETRY 
Flow cytometry was used to assess the changes in the major immune cell populations and 
immune activation markers. Whole peripheral blood, LN cell suspensions, and intestinal 
mononuclear cell suspensions were stained with fluorescently labeled antibodies to markers CD3 
(clone SP34-2; all antibodies from BD Bioscience, San Jose, CA, USA unless otherwise noted), 
CD4 (clone L200), CD8 (clone 3B5, Invitrogen Carlsbad, CA, USA), Ki-67 (clone B56), and 
HLA-DR (clone L243). For the detection of Ki-67, we employed an intracellular staining 
technique in which cells were stained with the surface markers, then fixed, permeabilized, and 
stained for Ki-67. Flow cytometry acquisitions were performed on an LSR II flow cytometer and 
analyzed with FlowJo software (Treestar, Ashland, OR, USA). 
4.4 VIRAL QUANTIFICATION QPCR 
SIVsab92108 plasma VLs were quantified with an SIVsab-specific real-time PCR (59). 
Viral RNA was extracted from 540 μl of plasma using the QIAamp viral RNA extraction kit
(QIAGEN, Courtaboeuf, France). Real-time (RT) PCR assays specific for each virus were 
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developed for SIVagm RNA quantification. Briefly, total RNA was retrotranscribed into cDNA 
by use of the TaqMan Gold RT PCR kit and random hexamers (PE, Applied Biosystems, Foster 
City, CA). PCRs were carried out in a spectrofluorometric thermal cycler (ABI PRISM 7700; 
PE). For SIVsab, quantification was based on the amplification of a 180-bp-located long terminal 
repeat (LTR) region. The primers and probe for SIVsab were J15S (5′-CTG GGT GTT CTC 
TGG TAA G-3′), 5′ J15S (5′-CAA GAC TTT ATT GAG GCA AT-3′), and J15P (6-
carboxyfluorescein-CGA ACA CCC AGG CTC AAG CTG G-6-carboxytetramethylrhodamine) 
as previously described (18). SIVsab cDNA was added to the universal master mix (PE, Applied 
Biosystems), containing 10 μM of each primer and 10 μM of the probe. The PCR mix contained 
the SIVsab cDNA, 2× universal SybrGreen master mix buffer (Applied Biosystems, 
Courtaboeuf, France), and primers in a final concentration of 0.3 μM. All PCRs were carried out 
in duplicate in parallel to a negative non-reverse transcription control reaction. The PCR cycling 
conditions were identical for all assays: a first cycle of denaturation (95°C, 10 min) was followed 
by 45 cycles of denaturation (95°C, 10 s), annealing (50°C, 30 s), and extension (72°C, 30 s). 
Absolute viral RNA copy numbers were deduced by comparing the relative signal strengths to 
corresponding values obtained for five 10-fold dilutions of standard RNAs that were reverse 
transcribed and amplified in parallel. In order to construct these RNA standards, larger LTR 
regions of SIVsab and SIVsmm were PCR amplified. The SIVsab LTR PCR product was 
obtained by amplifying a SIVsab reference virus (plasmid psab-1) in a PCR with primers LTR2A 
(5′-AAC TAA GGC AAG ACT TTA TTG AGG-3′) and LTR4S (5′-ACT GGG CGG TAC TGG 
GAG TGG CTT-3′). The PCR products were cloned into a pCR 2.1 vector (Invitrogen, 
Groningen, Netherlands). In vitro transcription was then performed using the MEGAscript kit 
(Ambion, Austin, TX). Known amounts of the SIVsab LTR standard RNAs were used to 
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determine the target copy numbers. The detection limit of the SIVsab quantification assays was 5 
× 10
2
 RNA copies/0.5 ml of plasma.
 For the quantification of SIVsmmD215, we also employed a specific real-time PCR 
assay, as described (20). Plasma viral loads were determined by branched DNA assay (bDNA; 
Bayer Diagnostics, Tarrytown, NY). 
4.5 IMMUNOHISTOCHEMICAL (IHC) ASSESSMENT OF HRFS 
IHC was performed on formalin-fixed or 4% paraformaldehyde-fixed, paraffin-embedded 
tissue samples. Four µm thick sections were deparaffinized in xylene, rehydrated in ethanol 
gradient (100, 100, 90, 75), and rinsed in dH20. For antigen retrieval, the sections were 
microwaved for 23 minutes in Vector Unmasking Solution (Vector Laboratories, Burlingame, 
CA). To deactivate endogenous peroxidases, the sections were treated with 3% hydrogen 
peroxide for 15 minutes. Slides were blocked with Dako blocking serum for 30 minutes (Dako, 
Carpinteria, CA).  Sections were incubated with primary antibody (see Table 1) for an hour at 
room temperature. Vector Vectastain ABC Elite Kit provided animal specific secondary antibody 
and Avidin-Biotin complex both incubated for 30 minutes (Vectastain Elite ABC kit; Vector 
Laboratories, Burlingame, CA). 1X PBS was used for rinses in between steps. For visualization, 
sections were treated with DAB (Dako, Carpinteria, CA), counterstained with hematoxylin and 
mounted in xylene based mounting medium with glass coverslips. Either Isotype or appropriate 





Table 1. Primary Antibodies and Dilutions Utilized in IHC Staining of HRFs. 
Primary 
Antibody 
Type Dilution Company Catalog # 
TRIM5α Polyclonal Goat 1:200 Abcam ab4389 
MX2 Polyclonal Rabbit 1:250 Novus Biologicals NBP1-81018 
APOBEC3G Polyclonal Rabbit 1:500 Novus Biologicals NBP1-88592 




Tetherin Monoclonal Rabbit 1:100 Abcam ab134061 
 
4.6 QUANTIFICATION OF IHC 
IHC stained slides were photographed at an overall magnification of 50x and unedited for 
quantification. Individual images of the LNs were stitched together using Image stitching feature 
of FIJI imaging software (27). DAB color was separated out from tissue samples using Color 
Deconvolution feature of FIJI imaging software on the hematoxylin and DAB setting (69). The 
color threshold was set visually per marker and percent area positive was quantified by pixel 
using color threshold and measure tools in FIJI imaging software (27). See Figure 1 for a 
photographical representation of quantification. The averages for each time point were calculated 
and compared against the preinfection levels to calculate fold change in expression. For the 
aggregated restriction factor quantification fold changes were added together. 
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Individual images of partial lymph nodes were stitched together to created composite Lymph node image. 
Composite images were cropped to include only lymph tissue. Color Deconvulution tool was used to isolate DAB 
pigment and Color Threshold tool to select for positive DAB signal to quantify percent positive area measurement. 
 
Figure 1. DAB Quantification Schematic. 
4.7 IMMUNOFLUORESCENCE (IF) STAINING 
Immunofluorescence staining (IF) was performed on formalin-fixed or 4% 
paraformaldehyde-fixed, paraffin-embedded tissue samples. Four µm thick sections were 
deparaffinized in xylene, rehydrated in ethanol gradient (100, 100, 90, 75), and rinsed in dH20. 
For antigen retrieval, the sections were microwaved for 23 minutes in Vector Unmasking 
Solution (Vector Laboratories, Burlingame, CA). Slides were blocked with Dako blocking serum 
for 30 minutes (Dako, Carpinteria, CA).  Primary antibodies were incubated for 1hour, followed 
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by 30 minute incubation with secondary antibody. All secondary antibodies were diluted to 
match the concentration of primary antibody. Please see Table 2 for primary antibody 
information and Table 3 for secondary antibody information. Slides were rinsed in 1XPBS or 
dH20 in between steps and mounted with Fluorescent mounting medium (Dako, Carpinteria, 
CA). Sections were photographed under oil immersion at 600x. 
 
Table 2. Primary Antibodies and Dilutions Utilized in IF Staining of HRFs. 
Primary Antibody Type Dilution Company Catalog # 
TRIM5α Polyclonal Goat 1:100 Abcam ab4389 
MX2 Polyclonal Rabbit 1:125 Novus Biologicals NBP1-81018 
APOBEC3g Polyclonal Rabbit 1:250 Novus Biologicals NBP1-88592 
SAMHD1 Polyclonal Goat 1:50 Santa Cruz Biotechnology SC-86212 
Tetherin Monoclonal Rabbit 1:50 Abcam ab134061 
CD11c Mouse IgG2a 1:50 Novacastra CD11c-563 
HAM56 Mouse IgM 1:100 Dako M 0632 
CD3 Rabbit polyclonal 1:50 Dako M 7254 
CD3 Mouse monoclonal 1:50 Dako A 0452 
CD 68 Mouse IgG1 1:50 Dako M 0814 
 
Table 3. Secondary Antibodies and Dilutions Utilized in IF Staining of HRFs. 
Secondary Antibody Type Company Catalog # 
Alexafluor Donkey α Goat 633 IgG Molecular Probes A-11055 
Alexafluor Donkey α Rabbit 488 IgG Molecular Probes A-21206 
Alexafluor Goat α Mouse 488 IgG1 Molecular Probes A-21121 
Alexafluor Goat α Mouse 488 IgG2a Molecular Probes A-21131 
Alexafluor Goat α Mouse 633 IgG1 Molecular Probes A-21126 
Alexafluor Goat α Mouse 633 IgG2a Molecular Probes A-21136 





4.8 SGA OF SIVAGM ENV GENES. 
To assess the diversity of virus quasispecies at different times post infection and assess 
the frequency of G-to-A hypermutation, insertions, or deletions that might illustrate the impact of 
the HRFs on the controlled virus, we used single-genome amplification (SGA) of viral 
sequences, as described previously (22, 64). Briefly, viral RNA was extracted from plasma 
samples with an EZ1 virus minikit (version 2.0; Qiagen, Valencia, CA) and reverse transcribed 
using primer SIVagmENVoutR (5′ GTACCTGGCCCATCAGTGTAATTCTGC-3′) and 
SuperScript III reverse transcriptase. The first-strand-synthesis reaction mixture contained 1× 
reverse transcription buffer, 0.5 mM each deoxynucleoside triphosphate, 5 mM dithiothreitol, 2 
units/μl of RNaseOUT reagent, 10 units/μl of SuperScript III reverse transcriptase, and 0.25 μM 
antisense primer. Dilutions of this cDNA were distributed in replicates of 16 PCRs to determine 
the dilution at which no more than 30% of reactions yielded amplicons, to ensure that most 
positive reaction mixtures contained a single template molecule. Full-length env genes were 
amplified by nested PCR using 1st-round sense primer SIVagmENVoutF (5′-
CAGGTGCTGTAAGCCCAAGACACATC-3′), 1st-round antisense primer SIVagmENVoutR 
(5′-GTACCTGGCCCATCAGTGTAATTCTGC-3′), 2nd-round sense primer SIVagmENVinF 
(5′-GCTATCATTGTCCGCTTTGCTTCACTC-3′), and 2nd-round antisense primer 
SIVagmENVinR (5′-CTCACTGGGAAGCCAACCTCTTCTTC-3′). PCR was performed using 
Platinum Taq High Fidelity polymerase (Invitrogen, Carlsbad, CA) in the presence of 1× PCR 
buffer, 2 mM MgSO4, 0.2 mM each deoxynucleoside triphosphate, 0.2 μM each primer, and 
0.025 units/μl of polymerase in a 20-μl reaction mixture. PCR conditions were 94°C for 2 min, 
followed by 35 cycles of 94°C for 15 s, 56°C for 30 s, and 68°C for 5 min (first round) or 45 
cycles with a 59°C annealing temperature (second round), followed by a final extension of 10 
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min at 68°C. Amplicons were inspected using 96-well E-gels (Invitrogen) and directly 
sequenced. 
Highlighter plots were created using Highlighter for Nucleotide Sequences v2.2.3 tool 
from the LANL HIV sequence database (32). APOBEC3g mutation analysis was done with 
HYPERMUT tool from the LANL HIV sequence database (68). 
4.9 MICROSCOPY AND PHOTOGRAPHY 
All photographs were taken on Zeiss AX10 Imager M.1 fluorescent microscope with 
Axiocam MRc5 camera and Axio Vision SE64 Rel 4.8 software package under brightfield or 
fluorescent settings. Photos were color enhanced and cropped using Adobe Photoshop Elements 
9 software package. 
4.10 GRAPHING AND STATISTICAL ANALYSIS 
All graphs and statistical analyses were generated using GraphPad Prism version 6 
software. In each species, post infection time point values for each HRF were compared with 
preinfection values using the nonparametric Mann-Whitney test. All statistical values of P < 0.05 
were considered statistically significant.  
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5.0  RESULTS 
5.1 AIM 1: COMPARE AND CONTRAST THE NATURAL HISTORY AND THE 
OUTCOME OF SIVSAB OR SIVSMM INFECTION IN GUINEA BABOONS (PAPIO 
PAPIO). 
SIVsab and SIVsmm infection of Guinea baboons. Of the six Guinea baboons IV 
infected with SIVsab92018, four were followed for more than 6 months post infection (p.i.). The 
remaining ones died during the follow-up from causes unrelated to SIV infection (complications 
of the surgery). During the acute infection, two out of six SIVsab infected baboons (DB 97, 
ED01) showed significant lymphadenopathy. No other clinical sign of acute SIV infection was 
observed during the follow-up. None of the SIVsab infected baboons had any clinical sign of 
HIV-associated immune deficiency at the end of the follow-up and all the biological parameters 
were back at the preinfection levels. 
The four Guinea baboons infected with SIVsmm were followed for 8 months pi. During 
the acute infection they did not show any clinical signs of disease. During the follow-up, two out 
of four SIVsmm infected baboons (CG13, and DK23) started to lose weight and showed 
lymphadenopathy, suggestive for disease progression.  
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5.1.1 Viral Loads 
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(A) SIVsab controlled infection in baboons. (B) SIVsmm persistent, pathogenic infection in baboons 
 
Figure 2. Plasma viral loads in controlled and persistent pathogenic SIV infection. 
 
The viral loads were closely monitored in the two groups of baboons throughout the 







(Figure 2A); while in the SIVsmm infected baboons the viral 




(Figure 2B). The SIVsab infected baboons controlled the 
virus very rapidly, as early as 28 dpi. Control was maintained throughout the follow-up.  In stark 
contrast, the SIVsmm infected baboons only partially controlled viral replication, reaching a viral 
set point of 10
5
 RNA copies/mL by 42 dpi. The SIVsmm VLs were maintained at these relatively 
high levels throughout the follow-up, with the exception of the most recent time points when 
significant increases of the levels of viral replication, suggestive for disease progression, were 
observed in two (CG13, DK23) of the four SIVsmm infected baboons. These results corroborate 
the clinical data and are in agreement with the pathogenic, progressive nature of HIV-2 infection 
in the baboons, as previously reported (44).  In the AGMs, the VLs showed the classic pattern of 
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 vRNA copies/ml) 




 vRNA copies/ml maintained throughout the follow-up 
(data not shown). 
5.1.2 CD4+ T lymphocyte cell counts 
CD4
+
 T cell counts are another important indicator of pathogenicity and disease 
progression (51).  In our study, both peripheral (Figure 3A,B) and intestinal (Figure 3C,D) 
CD4
+
 T cells decreased in SIVsmm infected baboons and remained virtually unchanged in the 
SIVsab infected baboons. The differences between the two baboon groups were more drastic in 
the intestine CD4
+
 T cells, albeit a moderate mucosal CD4
+
 T cell depletion could be observed in 
two baboons that presented the highest viral loads. In the remaining baboons, SIVsab infection 
resulted in a minimal and transient depletion of the mucosal CD4
+
 T cells , which were rapidly 
restored during the follow-up (Figure 3C). Conversely, in SIVsmm infected baboons, a sharp 
decline of the mucosal CD4
+
 T cells occurred by 21 dpi. This CD4
+
 T cell decline continued 
during the chronic stage of infection, the levels of CD4
+
 T cell restoration at the mucosal site 
being minimal in SIVsmm infected baboons (Figure 3D). A severe decline in CD4
+
 T cells is an 
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 T cells in baboons infected with SIVsab or SIVsmm, respectively. (C,D) Mucosal CD4
+
 T 
cell in baboons infected with SIVsab or SIVsmm, respectively. Index level is defined as a comparison of percent 
CD4
+
 T cell population in comparison to baseline percent  CD4
+
 T cell population. 
 
Figure 3. Changes in the CD4
+
 T cell levels in SIVsab and SIVsmm infected baboons. 
 
5.1.3 CD4+ T Lymphocyte immune activation 
Chronic immune activation is the best indicator of HIV/SIV disease progression, being 
more closely associated with progression than the levels of viral replication or the CD4
+
 T cell 
depletion (58). Therefore, we next assessed the levels of immune activation and T cell 
proliferation between the two groups of baboons. We employed two well-studied markers for 
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immune activation Ki-67, a cell proliferation marker, and HLA-DR, a MHC-II marker which is 
used to assess the levels of T cell immune activation. In the controller baboons, Ki-67 transiently 
increased during acute infection, but rapidly returned to preinfection levels throughout the 
follow-up (Figure 4A). Unlike the controller baboons, the progressor baboon Ki-67 levels 
progressively increased throughout chronic infection (Figure 4B).  
HLA-DR increased transiently during acute SIVsab infection in the controller baboons, 
but returned to preinfection levels by late chronic infection (Figure 4C). Conversely, in the 
progressor baboons, HLA-DR remained close to preinfection levels during the early stages of 
infection and only showed a sharp increase during late chronic infection (Figure 4D). Overall, 
immune activation levels returned to preinfection levels in the controller baboons, but 
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(A,B) Expression of KI-67 activation marker by peripheral CD4+ T cells in baboons infected with SIVsab or 
SIVsmm, respectively. (C,D) Expression of HLA-DR activation marker by  peripheral CD4+ T cells in baboons 
infected with SIVsab or SIVsmm, respectively  
 
Figure 4. Comparative dynamics of CD4+ T cell immune activation in controller (SIVsab infected) and 
progressor (SIVsmm infected) baboons.  
 
5.1.4 CD8+ T Lymphocyte immune activation 
CD8
+
 T cell immune activation patterns were similar to those of CD4
+
 T cells, with a 
transient increase in the controller baboons and persistent and progressive increases in the 
progressors. (Figure 5)   
HLA-DR expression on CD8+ T cells peaks around day 21 post infection in controller 
baboons, as seen in Figure 5C, remains increased through early chronic infection, but returns to 
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preinfection levels by late chronic infection.  In progressor baboons, HLA-DR expression 
sharply increases by 28, declines to nearly preinfection levels through early chronic infection, 
then sharply increases during late chronic infection (Figure 5D).  
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(A,B) Expression of KI-67 activation marker by peripheral CD8+ T cells in baboons infected with SIVsab or 
SIVsmm, respectively. (C,D) Expression of HLA-DR activation marker by  peripheral CD8+ T cells in baboons 
infected with SIVsab or SIVsmm, respectively. 
 
Figure 5. Comparative dynamics of CD4+ T cell immune activation in controller (SIVsab infected) and 
progressor (SIVsmm infected) baboons.  
 
35 
5.1.5 SA1 Results Summary 
Based on the infection outcome (progressive vs. controlled) and on the major difference 
in key biological parameters of SIV infection (viral load, CD4+ T cell counts, and immune 
activation), SIVsab and SIVsmm have completely different natural histories in a single NHP 
species, the Guinea baboon. Therefore, our study successfully developed an ideal in vivo 
environment to model the impact of HRFs on cross-species transmitted SIV infections. SIVsab-
infected baboons controlled the virus rapidly, preventing/restoring CD4+ cell depletion and 
successfully limited T cell activation. Consequently, SIVsab infected baboons permit us to 
monitor the contribution of HRFs to the control of SIV infection upon cross-species 
transmission. Conversely, SIVsmm induced persistent, progressive infection in baboons, with 
high chronic set-point levels of viral replication and increase in VLs, persistent CD4
+
 T cell 
depletion, and chronic immune activation. SIVsmm infected baboons can be employed to 
decipher the requirements for a successful cross-species transmission. While many factors may 
play a role in these differences, we assessed the role of HRFs in driving these different outcomes 
of SIV infection by focusing on APOBEC3g, MX2, SAMHD1, Tetherin, and TRIM5α in these 
cross-species transmission models. 
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5.2 TO DIRECTLY ASSESS THE CHANGES IN HOST RESTRICTION FACTORS 
THAT MAY CORRELATE WITH VIRUS CONTROL UPON CROSS-SPECIES 
TRANSMISSION. 
To investigate the correlates of virus control/persistence upon cross-species transmission, 
we next turn our attention to the dynamics of expression of known HRFs in baboons infected 
with either SIVsab or SIVsmm. At the time when this study was initiated, four such factors were 
known and we optimized IHC methods for each of them. During the study, MX-2 war further 
identified as a restriction factor and we optimized a new assay to monitor its expression during 
controlled and progressive cross-species transmitted infections. HERC5 was reported in May 
2014 and we have yet to develop a quantification system for this additional HRF. 
 
5.2.1 APOBEC3g 
The IHC assessment of APOBEC3g expression dynamics over the course of infection 
indicated an increase in APOBEC3g expression in SIVsab infected baboons that is coicidental 
with viral control (Figure 6). The progressor baboons infected with SIVsmm and AGM natural 
hosts had relatively consistent expression of APOBEC3g over the course of infection.  
Expression of APOBEC3g was generally located in the LN paracortex in the areas directly 
surrounding the lymphoid follicles, as well as the cortical sinuses.  
Quantification of the DAB signal (Figure 7), confirmed that APOBEC3g expression 
peaked at the point of viral control (29 dpi) at four-fold higher than baseline expression. 
APOBEC3g expression remained elevated three-fold above the baseline into chronic infection in 
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the controller baboons. The progressor baboons and natural hosts had a slight increase from 
preinfection levels. 
Immunofluoresence staining showed that the cell types responsible for the increased 
APOBEC3g expression are innate and adaptive immune cells (as shown by the colocalization of 
APOBEC3g marker with expressing CD11c, HAM56, and CD3) (Figure 8).  
 
Representative images of immunohistochemistry staining in lymph nodes from preinfection (D0), set point (D29), 
and chronic infection (D50+). All images at 50x magnification.  
 
Figure 6. Dynamics of APOBEC3g expression in baboons infected with SIVsab, SIVsmm, and in AGMs 
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Graphical representation of whole lymph node quantification of APOBEC3g expression throughout SIV infection of 
baboons and AGMs.  The average area percent  positive were converted to fold change from preinfection levels at 
peak, set point (SP), early chronic (EC) and late chronic (LC) in controller baboons, progressor baboons, and 
AGMs.  Data points are means from baboons infected with SIVsab (n=6), SIVsmm (n=4), and AGMS infected with 
SIVsab (n=16) 
 





Combination staining of APOBEC3g (green), CD11c/HAM56 (red), and merged image of double stain. Images 
photographed at 600x. 
 
Figure 8. Immunofluorescence images of lymph nodes in SIVsab baboon at peak of HRF expression.   
 
5.2.2 TRIM5α 
The IHC assessment indicated an increase in TRIM5α expression which occurred at the 
timepoint of viral control in SIVsab infected baboons (Figure 9). Conversely, the progressor 
baboons infected with SIVsmm appeared to express relatively constant levels of TRIM5α 
throughout infection, similar to the AGM natural host (Figure 9). At the peak of expression,   
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TRIM5α was generally located in the LN paracortex, but also in the mantle zone of the lymphoid 
follicles in the controller baboons 
Quantification of the DAB signal (Figure 10), confirmed the TRIM5α expression peak 
coincidental with viral control (29 dpi) at levels two fold higher than the  preinfection expression 
levels in controller baboons. During chronic infection, TRIM5α expression returned to 
preinfection levels. Signal quantification also demonstrated that, at the peak of viral replication, 
TRIM5α expression was lower than the baseline preinfection levels in both the progressor 
baboons and the AGM natural host  and returned to preinfection levels during chronic infection  
in progressor babons. TRIM5α expression in AGMs remained  decreased below preinfection 
levels during chronic infection 
Immunofluoresence staining showed that the cell types responsible for the increased 
TRIM5α expression are both innate and adaptive immune cells (as shown by the colocalization 




Representative images of immunohistochemistry staining in lymph nodes from preinfection (D0), set point (D29), 
and chronic infection (D50+). All images at 50x magnification.  
 
Figure 9. Dynamics of TRIM5α expression in baboons infected with SIVsab, SIVsmm, and in AGMs infected 
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Graphical representation of whole lymph node quantification of TRIM5α expression throughout SIV infection of 
baboons and AGMs.  The average area percent  positive were converted to fold change from preinfection levels at 
peak, set point (SP), early chronic (EC) and late chronic (LC) in controller baboons, progressor baboons, and 
AGMs. Data points are means from baboons infected with SIVsab (n=6), SIVsmm (n=4), and AGMS infected with 
SIVsab (n=16) 
 






Combination staining of CD11c/CD68/CD3 (green), TRIM5α (red), and merged image of double stain. Images 
photographed at 600x. 
 
Figure 11. Immunofluorescence images of lymph nodes in SIVsab baboon at peak of HRF expression.   
5.2.3 Tetherin 
The IHC assessment identified a dramatic increase in tetherin expression coincidental 
with viral control in SIVsab infected baboons. Tetherin expression then remained increased 
throughout the follow-up (Figure 12). Conversely, the progressor baboons infected with 
SIVsmm appeared to express relatively constant levels of tetherin throughout infection, similar 
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to the AGM natural host (Figure 12). Tetherin was generally expressed in the LN paracortex and 
the cortical sinuses. 
Quantification of the DAB signal (Figure 13), confirmed the tetherin expression peak 
coincidental with viral control (29 dpi) at levels six fold higher than the preinfection levels. This 
increased expression persisted throughout the chronic infection in the controller baboons. In the 
progressor baboons, tetherin expression was double the baseline preinfection levels at the viral 
setpoint and remained slightly elevated during chronic infection. Finally, in the SIVagm infected 
AGMs, tetherin expression was fairly constant throughout infection. 
Immunofluoresence staining showed that the cell types responsible for the increased 
tetherin expression are innate and adpative immune cells (as shown by the colocalization of 





Representative images of immunohistochemistry staining in lymph nodes from preinfection (D0), set point (D29), 
and chronic infection (D50+). All images at 50x magnification.  
 
Figure 12. Dynamics of Tetherin expression in baboons infected with SIVsab, SIVsmm, and in AGMs infected 
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Graphical representation of whole lymph node quantification of tetherin expression throughout SIV infection of 
baboons and AGMs.  The average area percent  positive were converted to fold change from preinfection levels at 
peak, set point (SP), early chronic (EC) and late chronic (LC) in controller baboons, progressor baboons, and 
AGMs. Data points are means from baboons infected with SIVsab (n=6), SIVsmm (n=4), and AGMS infected with 
SIVsab (n=16) 
 
Figure 13. Tetherin levels increase seven fold in controller baboons at point of viral control and in late 





Combination staining of Tetherin (green), CD11c/HAM56 (red), and merged image of double stain. Images 
photographed at 600x. 
 
Figure 14. Immunofluorescence images of lymph nodes in SIVsab baboon at peak of HRF expression. 
 
5.2.4 MX2 
The IHC assessment of MX2 expression dynamics over the course of infection identified 
an increased MX2 expression in the controller baboons (Figure 15). Conversely, the progressor 
baboons infected with SIVsmm appeared to express relatively constant levels of MX2 
throughout infection, similar to the AGM natural host (Figure 15).  MX2 was generally 
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expressed in the LN paracortex and cortical sinuses. At the peak of  MX2 expression, positive 
signals were also found in the mantle zone of lymphoid follicles. 
Quantification of the DAB signal (Figure 16), showed that MX2 expression peaked at  
seven fold increase compared to baseline preinfection levels coincidental with the peak of viral 
replication (10 dpi) and remained increased (3-fold) at the time of viral control (29 dpi). In both  
progressor baboons and AGMs expression of MX2 remained virtually unchanged from 
preinfection levels throughout infection. 
Immunofluoresence staining showed that the cell types responsible for the increased 
MX2 expression are innate and adaptive immune cells (as shown by the colocalization of MX2 




Representative images of immunohistochemistry staining in lymph nodes from preinfection (D0), set point (D29), 
and chronic infection (D50+). All images at 50x magnification.  
 
Figure 15. Dynamics of MX2 expression in baboons infected with SIVsab, SIVsmm, and in AGMs infected 
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Graphical representation of whole lymph node quantification of MX2 expression throughout SIV infection of 
baboons and AGMs.  The average area percent  positive were converted to fold change from preinfection levels at 
peak, set point (SP), early chronic (EC) and late chronic (LC) in controller baboons, progressor baboons, and 
AGMs. Data points are means from baboons infected with SIVsab (n=6), SIVsmm (n=4), and AGMS infected with 
SIVsab (n=16) 
 






Combination staining of MX2 (green), CD11c/HAM56 (red), and merged image of double stain. Images 
photographed at 600x. 
 
Figure 17. Immunofluorescence images of lymph nodes in SIVsab baboon at peak of HRF expression.   
5.2.5 SAMHD1 
Differently from all the other HRCs, the IHC  SAMHD1 expression remained virtually 
unchanged during SIVsab infection in the controller baboons (Figure 18). Furthermore, 
SAMHD-1 expression also remained virtually unchanged in the progressor baboons infected 
with SIVsmm and in the AGM natural host of SIVsab, with only slight increases being observed 
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in progressor baboons at the late chronic time points. SAMHD1 was generally expressed in the 
LN paracortex and in the cortical sinuses. 
Quantification of the DAB signal (Figure 19) confirmed the IHC observations and 
showed only a 1.5-2-fold increases in SAMHD-1 expression in the late chronic time points in 
progressor baboons. An explanation for this the lack of increase in SAMHD-1 expression in 
controller baboons is that SIVsab does not contain a vpx gene, which is the known antagonist of 
SAMHD-1. Interestingly, progressor baboons, which were infected with SIVsmm, the prototype 
virus containing a vpx gene exhibited a higher expression of SAMHD-1 than controllers.  
Immunofluoresence staining showed that the cell types responsible for the increased 
SAMHD-1 expression are both innate and adaptive immune cells (as shown by the colocalization 




Representative images of immunohistochemistry staining in lymph nodes from preinfection (D0), set point (D29), 
and chronic infection (D50+). All images at 50x magnification.  
 
Figure 18. Dynamics of SAMHD1 expression in baboons infected with SIVsab, SIVsmm, and in AGMs 
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Graphical representation of whole lymph node quantification of SAMHD1 expression throughout SIV infection of 
baboons and AGMs.  The average area percent  positive were converted to fold change from preinfection levels at 
peak, set point (SP), early chronic (EC) and late chronic (LC) in controller baboons, progressor baboons, and 
AGMs. Data points are means from baboons infected with SIVsab (n=6), SIVsmm (n=4), and AGMS infected with 
SIVsab (n=16) 
 





Combination staining of CD11c/HAM56/CD3 (green), SAMHD1 (red), and merged image of double stain. Images 
photographed at 600x 
 
Figure 20. Immunofluorescence images of lymph nodes in SIVsab baboon at peak of HRF expression.   
 
5.2.6 Aggregation of Five markers 
Our results identified a clear trend for increased expression of HRFs in controlled 
infection and relatively constant expression throughout the progressive infection. However, none 
of these increases reached statistical significance, due to either a high variability between 
animals and to the relatively small number of animals included in this study. While each of this 
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factors could impact the virus at different time points of the virus cycle, we reasoned that the 
overall expression of the HRFs is illustrative for their combined action of these factors rather 
than the individual values. Therefore, in order to conclude the importance of these factors on the 
control of infection, we aggregated their impact by adding the quantification results for each of 
the individual factors. Results are shown in Figure 21, and clearly demonstrate that the increase 
in HRF expression is significant at the time points preceding and coinciding with viral control 
(p<0.005). Conversely, in either baboons infected with SIVsmm or AGMs infected with SIVsab, 
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Sum aggregation of fold expression changes of five HRFs tested previously. Statistical significance is based on non-
parametric Mann-Whitney test with significance of P<0.005. 
 
Figure 21. Aggregated fold increase (sum) expression of host restriction factors significantly increases at point 




5.2.7 SA2 results summary 
Four of five HRFs tested had increased expression in the LNs of the controller baboons 
coincidental with viral control as demonstrated visually by IHC and quantitatively by whole LN 
quantification.  No significant increase in HRF expression occurred in the progressor baboons or 
in the natural AGM host. Additionally, these HRFs were found to be expressed in both innate 
and adaptive immune cell populations, all target cells of SIV. These differences in expression 
demonstrate in vivo that HRFs may play a critical role in the success or failure of a cross species 
transmission event. We therefore next focused on measuring the impact of intrinsic immunity on 
the virus to identify one of the mechanisms through which a cross-species transmitted infection 
can be controlled. 
5.3 AIM 3: TO ASSESS THE HRF IMPACT ON THE VIRUS IN CONTROLLED 
AND PROGRESSIVE INFECTIONS OF BABOONS. 
5.3.1 SGA analysis of env sequences from controller baboons 
Plasma samples collected at the peak of viral replication and at the last time point where a 
detectable viral load was observed were subjected to SGA and direct sequencing in an attempt to 
identify the imprint of intrinsic immunity on virus evolution. This approach had two major 
shortcomings: first, we could only select very early time points (before 29 dpi) that showed 
detectable viral loads. Second, the virus that we amplified was the one that was replication 
competent and, probably the least impacted by the restriction factors. Indeed, comparative 
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analyses of the viral diversity in three controller baboons (DB97, EA20, ED01), at the peak of 
viral load (10 dpi) and at the time of viral control (29 dpi) failed to identify a major impact of 
APOBEC3g on the virus (Figures 22-24), the rates of mutation being similar to those observed 
in the natural host of SIVsab, the AGM (data not shown).  Therefore, in a second attempt to 
document the impact of intrinsic immunity on virus evolution we performed SGA on the DNA 
from the PBMCs collected at the peak (10 dpi), set-point (42 dpi) and during the chronic 
infection (90 dpi) to document accumulation of defective viruses as a result of host restriction. 
Preliminary evidence points to a direct impact of APOBEC3g on viral control as hypermutation 
rates increase in the PBMC derived env from controller baboons DB97 from peak infection to 





(A) peak of viral replication (D10) and (B) viral control (D22). Highlighter tick colors correspond with the nucleotide as listed A:Green, T:Red, G:Orange, 
C:Light blue, IUPAC:Dark blue, Gaps:Gray. 
 
Figure 22. Highlighter Plot assessing the sequences of plasma SIV Env in controller baboon DB97. 
 
 








 (A) peak of viral replication (D10) and (B) viral control (D43). Highlighter tick colors correspond with the nucleotide as listed A:Green, T:Red, G:Orange, 
C:Light blue, IUPAC:Dark blue, Gaps:Gray. 
 
Figure 23. Highlighter Plot assessing the sequences of plasma SIV Env in controller baboon EA20. 
 
     
 A                                                     B 
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(A)  peak of viral replication (D10)  (B) during course of viral control (D22). Highlighter tick colors correspond with the nucleotide as listed A:Green, T:Red, 
G:Orange, C:Light blue, IUPAC:Dark blue, Gaps:Gray 
 











(A)  peak of viral replication (D10)  (B) during course of viral control (D44). Highlighter tick colors correspond with the nucleotide as listed A:Green, T:Red, 
G:Orange, C:Light blue, IUPAC:Dark blue, Gaps:Gray. APOBEC specific: Pink. 
 
Figure 25. Highlighter Plot assessing the sequences of PBMC derived SIV Env in controller baboon DB97.  
   
 A                                                      B 
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5.3.2 SA3 Results Summary 
There was no significant change in the mutation rates in the env sequence of SIV found in 
the plasma of the controller baboons from peak of infection to point of viral control.  Preliminary 
evidence points to a direct impact of APOBEC3g on viral control as hypermutation rates increase 
in the PBMC derived env from controller baboons DB97 from peak infection to the time of viral 
control. 
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6.0  DISCUSSION 
SIV cross-species transmission among NHPs and between NHPs and humans is an 
important area of study as both HIV-1 and HIV-2 jumped species to humans. Additionally, 
humans are exposed in Central/West-central Africa (i.e., the area of HIV emergence) to a 
plethora of highly divergent viruses related to HIVs. It is not well understood what factors 
determine the success or failure of a cross-species transmission event. To address these questions 
and to provide the scientific community with an adequate animal model for the study of the 
factors governing SIV cross-species transmission, we developed a new baboon animal model. It 
consists of the use of a single species of monkeys and two different viruses resulting in two 
completely opposed pathogenic outcomes: completely controlled SIV infection (in baboons 
infected with SIVsab) and persistent, progressive infection (in baboons infected with SIVsmm).  
Compared to the Asian RM non-natural host traditionally used, this model uses the African 
Guinea baboon non-natural host that lives sympatrically with the AGM natural host. Thus, a 
cross-species transmission event is plausible in the wild, where cross-species transmission events 
occur naturally. Furthermore, another innovation of our study is that differently from the 
majority of the in vivo approaches, we used unadapted plasma SIV stocks that predominantly 
contained transmitted founder strains which therefore have a similar resistance to IFNs as the 
strains that can be transmitted in natural cross-species transmissions.  
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In the past decade HRFs have been identified and rapidly changed the field of HIV study. 
As this is a newly growing field, most studies focus on one or two of the HRFs using mostly in 
vitro models. This study furthers the HRF field first by using an in vivo NHP model, and an 
experimental challenge approach that models natural transmission as closely as possible. Second, 
this study assessed the combined effect of multiple HRFs as a driving factor in cross-species 
transmission rather than individual action of the HRFs in artificial in vitro systems. While each 
factor is important, it is the combined action that will drive the overall response to cross-species 
transmission.  
Our protein expression quantification analysis suggests that, while the individual 
expressions of each HRF upon cross-species transmitted infections only marginally correlate 
with the virus control, their aggregated expression is clearly statistically associated with control 
of infection. While our analysis relied on the quantification of protein expression and not 
necessarily of protein action, our results clearly support that all together these proteins could be 
drivers of cross-species transmission. Our quantification was based on an innovative approach in 
which we quantified HRF expression on the whole lymph node rather than on common “regions 
of interest”. 
An indirect validation of our approach is represented by the results of SAMHD1 
quantification. This was the only HRF whose expression did not increase at the time of virus 
control in SIVsab infected baboons. This is not unexpected, as SAMHD1 acts through Vpx and 
SIVsab does not contain this accessory gene. Interestingly, in the pathogenic counterpart of the 
model, SAMHD1 increased at the time of disease progression. Note, however, that the increase 
in SAMHD1 expression was not directly correlated with disease progression. The significance of 
these changes in SAMHD1 expression with disease progression has to be further investigated. 
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Our results also support previous studies reporting that HRFs are expressed in relevant 
cell types that are the major target cells of HIV (12, 13, 28, 37, 75). We found that HRFs were 
expressed by dendritic cells, macrophages, and T cells, which are all major targets of HIV/SIV. 
As these are the physiologically relevant target cells, HRF expression in these cells is likely 
critical to virus restriction.  
Unexpectedly, SGA analysis revealed no significant changes in mutation rates in plasma 
virus. While virus subjected to the HRFs should ideally have a higher mutation rate or marks of 
intrinsic immunity pressures, our data suggest otherwise. However, we have initially attempted 
to characterize the impact on the plasma virus. By definition, the virus in plasma is replication 
competent and should a dramatic impact of the HRFs on the virus occurred, that virus would not 
have been present in plasma, as hypermutations, frame shifts, deletions and insertions rendering 
the virus impaired for replication would prevent such a virus to be present in large amounts in 
plasma. We therefore, recently reasoned that to assess the impact on viral quasispecies we should 
focus on the intracellular virus and performed SGA on the viral DNA contained in PBMCs and 
LNs. Upon completion of such assays, virus derived from PBMC’s does have higher instance of 
APOBEC associated mutations, indicating APOBEC3g induces hypermutation and indicates 
direct impact on  viral control. 
In summary, our study demonstrates a significant increase in HRF protein expression in 
controller baboons relative to virtually unchanged HRF expression in progressor baboons and 
natural hosts. This HRF expression increase occurs in the physiologically relevant HIV target 
cell populations, suggesting that viral restriction through HRFs is a key mechanism of control in 
vivo upon cross-species transmissions. While plasma virus env sequences showed no 
hypermutation, PBMC derived env showed an increase of APOBEC3g specific hypermutations 
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pointing to a direct effect of APOBEC3g on virus control. Overall, our study suggests that HRF 
expression does play a major role in the success or failure of cross-species transmission.  
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7.0  FUTURE DIRECTIONS 
While this study makes advancement in the understanding of what role HRFs play in 
cross-species transmission, much more progress can be made. Further staining and quantification 
of HRF activity at mucosal sites would benefit this study. Including the recently discovered 
HERC5 HRF in all assays would provide a more comprehensive view of host restriction. A 
combined IHC stain of all HRFs that can be performed simultaneously would also benefit this 
study. A combined stain could be quantified using the same quantification technique each 
individual marker was subjected to and produce more reliable results. Such an analysis is in 
progress.  
Additionally, the experiments performed in this study were based on IHC expression. 
IHC is a notoriously difficult assay to perform and the quantification techniques used have a 
mild degree of subjectivity. A qRT-PCR assay for each HRF would provide an excellent viral 
mRNA expression complement to the protein-based assays performed here. qRT-PCR 
quantification is less subjective than the quantification techniques used in this study. Note, 
however that, while less subjective, qRT-PCR is the quantification of mRNA, and not 
necessarily quantifying the expression of or action of each protein.  
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8.0  PUBLIC HEALTH SIGNIFICANCE 
This research has many applications to the field of public health. In particular 
understanding cross-species transmissions, of which HIV-1 and HIV-2 are products of, is 
essential to preventing the occurrence and spread of new HIVs and may help control the current 
HIV pandemic.  The use of an animal model is the closest possible way to model cross-species 
transmission that occurs in the wild. This research establishes a new baboon animal model for 
cross-species transmission, which is an essential part of HIV/AIDS research.  
The role of HRFs and what impact they may have in determining the success of cross-
species transmission is also important to public health. This research suggests that the collective 
action of multiple HRFs is a major determinant to the success of cross-species transmission and 
further understanding could prevent the establishment of new HIVs. In addition to cross-species 
transmission mediation, HRFs may provide many therapeutic opportunities to prevent or treat 
HIV infections in the future. 
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